Royalty Pharma plc (RPRX) Reports Q2 Revenue of $555 Million
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $59.45 +1.45%
Financial Fact:
General and administrative: 997K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
General and administrative: 997K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 revenue of $555 million, versus $511 million reported last year.
- Increased 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,080 to $2,120 million
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
